Market Trends of France Patient Monitoring Industry
The Neurology Segment is Expected to Show Healthy Growth in the Market Studied During the Forecast Period
The neurology segment is expected to witness significant growth in the patient monitoring market over the forecast period owing to factors such as the rising prevalence of neurological disorders such as Parkinson's, Alzheimer's, and dementia, the need to monitor neurological conditions regularly, and growing company activities in developing devices that help monitor brain activity.
The rising burden of neurological diseases among the population is the key factor driving the demand for neuromonitoring devices. For instance, the French Ministry of Health and Prevention, in April 2023, stated that around 272,500 patients in France suffer from Parkinson's, and 25,000 new cases are reported each year. This shows the high burden of neurological diseases such as Parkinson's, which can be monitored for loss of balance and slow movements, and increases the need for monitoring devices in the country.
Furthermore, the increasing product launches in the country may augment the availability of neuromonitoring devices in the market, which is expected to boost segment growth. For instance, in March 2022, BrainTale, a French MedTech, launched the brainTale-care platform with its modules brainQuant, dedicated to white matter quantification and brainScore-coma, offering the prediction of coma recovery. This launch provides neurologists and resuscitators with clinically verified solutions to enhance the monitoring of the progression of neurological diseases, influencing the decision-making process to optimize patient treatment.
Therefore, the neurology segment is expected to grow over the forecast period due to factors such as the high burden of neurological diseases and rising company activities.
The Cardiology Segment is Expected to Record a Significant Market Share Over the Forecast Period
The cardiology segment is expected to witness a significant market share in the patient monitoring market in France over the forecast period owing to factors such as the rising burden of cardiovascular disease and its risk-associated factors, as well as the growing adoption of cardiac monitoring devices.
Cardiac monitoring refers to the continuous or intermittent monitoring of heart activity by assessing the patient's condition relative to cardiac rhythm. Additional monitoring components allow cardiovascular pressures and cardiac output to be monitored and displayed as required for patient diagnosis and treatment.
The rising prevalence of hypertension, stroke, diabetes, obesity, and other cardiovascular diseases is the key factor driving the demand for cardiac patient monitoring equipment, hence bolstering segment growth. For instance, an article published in Dovepress in January 2022 observed that the incidence of myocardial infarction among the population living in France may double by 2035.
In addition to the above context, younger women are expected to suffer more from myocardial infarction than men. Thus, the expected increase in the population suffering from heart disease is anticipated to fuel the demand for cardiac monitoring devices to further reduce the risk of heart failure, propelling the segment's growth.
Additionally, obesity is considered to be a significant public health problem, leading to cardiac complications and increasing the need for patient monitoring devices in the country. For instance, according to the Obesity Atlas data released in March 2023, French adults face a concerning trend. The forecast predicts an obesity rate of 34% by 2035. This heightened risk of obesity not only raises the likelihood of cardiac diseases but also leads to a surge in the adoption of patient monitoring devices, consequently fueling growth in this segment through the forecast period.
Moreover, the increase in funding for developing monitoring devices that are used for detecting and monitoring heart conditions is also expected to bolster segment growth. For instance, in April 2022, Implicity raised EUR 21 million (USD 22.37 million) in Series A funding from Cr茅dit Mutuel Innovation and Bpifrance. With this funding, the company was expected to speed up the international rollout of its AI-based technology and cardiac data management solutions. Therefore, owing to factors such as the rising burden of obesity, coupled with cardiovascular diseases and new funding, the cardiology segment is expected to grow over the forecast period.
